Aveanna Raises 2026 Revenue Guidance to $2.56–2.58B, Targets $328M–332M EBITDA
AVAH•Aveanna Healthcare raised full-year 2026 revenue guidance to $2.56–2.58 billion and adjusted EBITDA to $328–332 million, driven by a one-time $6 million receivables collection in Q1. The company said the Medicare home health licensure moratorium won’t affect operations and expects the Family First deal to close in late Q2.
1. Q1 Results and Updated 2026 Guidance
Aveanna reported that Q1 benefitted from a one-time $6 million accounts receivable collection, boosting revenue and adjusted EBITDA. The company increased full-year 2026 revenue guidance to $2.56–2.58 billion and raised adjusted EBITDA outlook to $328–332 million, citing strong collections and operational efficiency.
2. Regulatory Moratorium Impact
Management confirmed the Home Health licensure moratorium, targeting new Medicare provider approvals, does not affect current operations or pending acquisitions. The company emphasized its compliance record and plans to engage with regulators to ensure reputable providers remain operational.
3. Family First Acquisition
Aveanna expects to close the Family First Homecare acquisition in late Q2 2026, positioning the company for expanded market share in private duty nursing. The deal supports long-term growth and is anticipated to integrate seamlessly with existing services.
4. Preferred Payer Strategy and Clinical Investments
In Q1, four new preferred payer agreements lifted private duty services preferred volume to 60%, advancing the 2026 target of eight agreements. Clinical initiatives yielded 21 out of 22 hospice locations with five-star ratings, supporting patient satisfaction and margins.
